Follow The Filings

ENTA Enanta Pharmaceuticals

Enanta Pharmaceuticals earnings company data as of 4:00 PM ET 11/22

  • 0 of 1 EPS beats

History

1 period, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2027 Q1 16 Nov EPS -0.77 -0.81 Miss
Rev $15.7M $12.9M Miss -18.1%

Insider trades

Open-market buys and sales by ENTA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ENTA insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 14 stock grants, 13 share withholdings for taxes, and 9 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
10-K
SCHEDULE 13G —
8-K 2.02,9.01
SCHEDULE 13G/A —
8-K 8.01
8-K 5.02,7.01,9.01
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
424B5
8-K 1.01,9.01
8-K 8.01
8-K 7.01,9.01
10-Q
8-K 2.02,9.01
SCHEDULE 13G/A —
8-K 8.01
8-K 5.02,5.07,9.01
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
SCHEDULE 13G/A —
DEF 14A

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf